Abstract [177Lu]Lu-PSMA radioligand therapy (LuPSMA RLT) has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), yet clinically meaningful response heterogeneity persists even among patients selected on the basis of PSMA PET positivity.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Nanhui
Contact Nanhui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack